Muscle-type carnitine palmitoyltransferase 1 (CPT1b) is considered to be the gene that controls fatty acid mitochondrial b-oxidation. A functional peroxisome proliferator-activated receptor (PPAR) responsive element (PPRE) and a myocite-specific (MEF2) site that binds MEF2A and MEF2C in the promoter of this gene had been previously identified. We investigated the roles of the PPRE and the MEF2 binding sites and the potential interaction between PPARa and MEF2C regulating the CPT1b gene promoter. Mutation analysis indicated that the MEF2 site contributed to the activation of the CPT1b promoter by PPAR in C2C12 cells. The reporter construct containing the PPRE and the MEF2C site was synergistically activated by co-expression of PPAR, retinoid X receptor (RXR) and MEF2C in non-muscle cells. Moreover, protein-binding assays demonstrated that MEF2C and PPAR specifically bound to one another in vitro. Also for the synergistic activation of the CPT1b gene promoter by MEF2C and PPARaRXRa, a precise arrangement of its binding sites was essential.
INTRODUCTION
The incorporation of activated long-chain fatty acids into the mitochondria, which are then catabolized through b-oxidation, is carried out by the mitochondrial carnitine palmitoyltransferase (CPT) system. CPT1 [reviewed in (1) ], the outer membrane component of this system, is the main regulatory step in the b-oxidation pathway. CPT1 is thus a suitable site for the pharmacological control of fatty acid oxidation, potentially useful in situations such as diabetes (2) or heart disease (3). CPT1 is encoded by at least two genes known as L-CPT1 (or -a) and M-CPT1 (or -b) on the basis of the tissues, liver (L-) or muscle (M-), where the expression of each one was first described. However, CPT1b is expressed, in addition to skeletal muscle, in heart, testis and brown and white adipose tissue, whereas CPT1a has a more widespread distribution. CPT1b expression increases in the heart after birth [in terms of V max , (4)] or after fasting [in terms of mRNA (5)] concomitant with an increase in circulating levels of fatty acids. This expression pattern may be of great significance since fatty acids are the major source of energy for heart, skeletal muscle and brown adipose tissue.
We (6) , and others (5,7), had shown that CPT1b is a target gene for the action of peroxisome proliferator-activated receptors (PPARs), nuclear receptor transcription factors that are regulated by fatty acids and derivative metabolites (8) (9) (10) (11) (12) (13) , and had localized a PPAR responsive element (PPRE) upstream of the first exon of this gene. There are three related PPAR family members, PPARa, PPARg and PPARd. According to several lines of evidence, PPARa, through the regulation of CD36/ FAT (14) , acyl-CoA synthetase (15) , CPT1b (5-7), CPTII (16) and medium-chain acyl-CoA dehydrogenase (17) stimulates, respectively, fatty acid transport into the cell, its activation, import into the mitochondria and b-oxidation.
In the human CPT1b gene promoter, the PPRE is flanked by one E-box motif and a myocite-specific (MEF2) binding site; this organization is highly conserved in the mouse, sheep and rat CPT1b gene (18) . The MEF2 site of the CPT1b gene binds MEF2A and MEF2C (19) , which are members of the MADS family of transcription factors that have been implicated in the regulation of muscle-selective gene expression (20) (21) (22) (23) (24) (25) . The PPARa-mediated regulation of the CPT1b gene is enhanced by the PPARg coactivator-1 (PGC-1) (26) that also interacts with MEF2C to up-regulate GLUT4 expression (27) or MEF2A to stimulate CPT1b expression (28) .To gain more insight into the tissue-specific control of CPT1b gene expression, we examined the basis of the specific expression of this gene in muscle cells. We conclude that the activity of the CPT1b promoter is controlled by a synergistic mechanism involving MEF2C and the heterodimer PPARa-RXRa, through a physical interaction between PPAR and MEF2C in a distance-dependent manner with sequences closely localized upstream of exon 1A.
MATERIALS AND METHODS

Plasmids
pCPTluc containing a 380 bp fragment of the human CPT1b gene was constructed by PCR using a pair of oligonucleotide primers, CPTF2 and CPTR2 (for sequences of all oligonucleotides used in this work, see Table 1 ), corresponding to coordinates À905 to À883 and À525 to À541 from the translation origin, respectively, of the human CPT1b gene, and pCPT-CAT (6) as template. After 10 cycles (94 C for 1 min; 58 C for 1 min and 72 C for 1.5 min), the amplified product was purified in a 1% agarose gel, and the KpnI-SmaI digest was cloned into pGL3Basic (Promega).
pCPTmutMEF, containing point mutations at the MEF-2 sequence, was obtained by site-directed mutagenesis overlapping extension PCR, as described previously (29) , using the oligonucleotides CPT-F2, CPT-R2, and mutMef-F and mutMef-R (which introduce a mutation in MEF-2 site).
pCPT-B211, containing 46 bp flanking de PPRE upstream of exon 1A of the CPT1b gene, was constructed by cloning in NheI-SmaI-digested pGL3Basic (Promega), two complementary oligonucleotides, CAS-F1 and CAS-R1. pCPT-B211mut-MEF2 was generated by digesting pCPT-B211 with BstEII and XhoI and cloning the oligonucleotides CAS-F3 and CAS-R3.
pCPT-M5 and pCPT-M10, containing either 5 or 10 bp between the MEF2 and the PPRE sites, respectively, were obtained by site-directed mutagenesis overlapping extension PCR, as described in (29) , using the oligonucleotides CPT-F2, CPT-R2, CPT-M5-F, CPT-M5-R, CPT-M10-F and CPT-M10-R pMEF2, containing the putative MEF-2 site, was obtained by cloning a pair of oligonucleotides (Mef-F and Mef-R) into the NheI-XhoI-digested pGL3Promoter. To confirm the sequence, all constructs were automatically sequenced using the fluorescent terminator kit (Perkin-Elmer).
pSG5-PPARa, pJCXRa and pCDNA-MEF2C contained the cDNAs for mouse PPARa, human RXRa and human MEF2C, respectively. pRL-CMV (Promega) contained the Renilla luciferase gene under the control of the cytomegalovirus (CMV) intermediate-early enhancer/promoter. PGEXhPPARa, producing a glutathione S-transferase (GST-full-length human PPARa fusion protein), has been described previously (16) .
Cell growth and differentiation
The CV-1 cells were cultured in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). Chinese hamster ovary (CHO) cells were cultured in Ham's F12 medium supplemented with 10% FBS. C2C12 myoblasts were grown in DMEM supplemented with 10% FBS (growth medium), and shifted to DMEM supplemented with 10% horse serum (HS) (differentiation medium) to allow acquisition of the myotube phenotype. All cells and subsequent experiments were maintained under 5% CO 2 at 37 C.
Transient transfection assays
Typically, 0. (30), and cells were harvested 48 h after transfection. For C2C12 cells, transfection FuGENE-6 reagent (Roche) was used, as indicated by the manufacturer; after 24 h in DMEM + 10% FBS, the medium was changed to DMEM + 10% HS to allow differentiation from myoblasts to myotubes, and 48 h later, cell extracts were obtained.
Firefly luciferase and Renilla luciferase assays
The cell extracts were prepared using the Passive Lysis Buffer method (Promega), and firefly and Renilla luciferase activities were determined in a TD-20/20 Luminometer (Turner Designs) using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's recommendations.
In vitro transcription and translation
MEF2C, PPARa and RXRa were transcribed and translated by using commercially available kits according to the manufacturer's instructions (Promega).
Electrophoretic mobility shift assay
An aliquot of 2.5 ml of each factor synthesized in vitro was preincubated on ice for 10 min in 10 mM Tris-HCl (pH 8.0), 40 or 100 mM KCl for PPAR or MEF2C, respectively, 0.05% (v/v) Nonidet P-40, 6% glycerol, 1 mM dithiotheitol and 2 mg of poly(dI-dC). The total amount of reticulocyte lysate was kept constant in each reaction through the addition of unprogrammed lysate. When indicated, 1.5 ml of specific antibody (anti-MEF2 from SantaCruz Biotechnology) was added to the reaction mixture. Next, 2 ng of probe, 32 P-labeled by 5 0 endlabeling with T4 polynucleotide kinase, was added and the incubation was continued for 15 min at room temperature. The final volume for all the reactions was 20 ml. Samples Table 1 . Oligonucleotides used for EMSA and constructions (see Materials and Methods for details)
Oligonucleotide Sequence
were electrophoresed at 4 C on a 4.5% polyacrylamide gel in 0.5% TBE buffer [45 mM Tris, 45 mM boric acid and 1 mM EDTA (pH 8.0)], and the gel was dried and exposed to an autoradiographic film.
GST-pull down assay
GST and GST-PPARa fusion proteins were expressed in Escherichia coli and purified on glutathione-sepharose beads (Amersham Pharmacia Biotech) as described previously (31) . Amounts and integrity of GST were checked by SDS-PAGE and Comassie Blue staining. 35 S-methionine labeled MEF2C (4 ml) was incubated in the presence of equivalent quantities of immobilized GST or GST-PPARa in 1 ml of binding buffer [NETN + 0.5% milk + protease inhibition cocktail (Sigma)] for 4 h at 4 C with agitation. Then the samples were centrifuged for 1 min at 2000 r.p.m. and the resin was washed twice with NETN at room temperature. After that the samples were boiled, mixed with 2· Laemli Buffer and resolved by SDS-PAGE. Labeled proteins were visualized by fluorograpy.
RESULTS
The response of CPT1b promoter to PPARa is cell line specific
In order to examine the responsiveness of the CPT1b gene to PPARa on different tissular contexts, we performed a series of transient transfections in several cell lines derived from different tissues: CV-1 (kidney), CHO (ovary) and C2C12 (muscle). pCPTluc, a plasmid containing a 380 bp fragment of the human CPT1b promoter ( Figure 1A ), was used as reporter. In all cells studied, the basal expression of the construct was similar (data not shown) but, unexpectedly, induction mediated by PPARa/RXRa was higher in C2C12 myotubes, in which a 38-fold induction from basal activity was observed ( Figure 1B) . Analysis of the 5 0 flanking region of the human CPT1b gene by the TFSEARCH routine showed the presence of a putative myogenic binding sequence (MEF-2 site) located at coordinates À759 to À744 from initial ATG, and neighboring the PPRE ( Figure 1A) . The higher PPARa responsiveness in C2C12 cells was correlated with the presence of proteins able to bind to MEF2 sites in the C2C12 nuclear extracts (data not shown). The positive correlation between the presence of such myogenic proteins and the increase in the response to PPARa observed in C2C12 suggested a mechanism of synergy between myogenic proteins and the heterodimer PPARa/RXRa.
The MEF-2 sequence binds MEF2C: mutation of these sequences affects PPARa responsiveness
We performed gel mobility shift assays to analyze whether MEF2C binds to the putative MEF2 site of the CPT1b gene. Figure 2A shows how, when the wild-type sequence (lanes 1-3) was used as a probe in electrophoretic mobility shift assays (EMSAs), in vitro-transcribed and in vitro-translated MEF2C was able to promote shifted bands, whereas the mutation of the MEF2 site (lanes 4 and 5) abolished such binding. Moreover, specific MEF2 antibodies promote a supershifted band (lane 3). To confirm the functional importance of this cis element on the transcriptional activity of the CPT1b promoter, we generated a construct in which one copy of the MEF-2 sequence was cloned upstream of an SV40-driven luc reporter and then transfected this plasmid in C2C12 cells. This plasmid showed an increased basal expression when compared to the empty vector ( Figure 2B ), thus identifying these sequence as a functional MEF2 binding site. To confirm the function of this site on the CPT1b gene promoter activity, we analyzed the effect of the overexpression of MEF2C on the activity of a luciferase reporter construct driven either by the wild type or a MEF2 site mutant version of the CPT1b promoter on CV-1 cells. Figure 2C shows how the response to MEF2C is eliminated by the mutation of the MEF2 site. To further investigate the synergy between MEF2C and PPARa, a luc reporter construct was generated in which a 46 bp fragment of the CPT1b gene promoter flanking the PPRE was cloned directly upstream of the luc gene (pCPT-B211). Furthermore, mutation of the MEF-2 site (pCPT-B211mutMEF2) was performed as well. When assaying relative basal activities for each plasmid in C2C12 cells ( Figure 2D ), we found that the mutation of the MEF-2 element, which did not affect the PPAR-RXR binding (Figure 2A; lanes 6-9) , surprisingly, did not affect basal activity in C2C12 cells but, in contrast, dramatically reduced the activity observed in the presence of PPARa/RXRa when compared to the wild-type promoter construct.
PPARa/RXRa and MEF2C cooperate at the transcriptional level in the CPT1b gene promoter
In order to check the synergy between MEF2C and the PPARa/RXRa, we carried out transient transfections in CV-1 cells using pCPTluc as reporter and assaying the effect of cotransfection with expression vectors for PPARa, RXRa and MEF2C. To analyze the effect of the presence of ligand, we performed these experiments using charcoal-stripped serum in combination with the presence or absence of a synthetic ligand for PPARa. As shown in Figure 3 , Figures 1-3 confirm the existence of a synergy between MEF2C and the heterodimer PPARa/RXRa. Because PGC-1 is known to interact with both PPAR and MEF2C, we examined whether PGC-1 might further augment the response of the CPT1b promoter to PPAR in C2C12 cells. As shown in Figure 4 , the presence of PGC-1 actually increases the response to PPAR.
MEF2C and PPARa physically associate in vitro
The cooperative effects of PPAR and MEF2C on transcriptional activation raise the possibility that these two proteins physically interact with each other. The direct and specific physical interaction of PPARa and MEF2C was examined by using in vitro protein-binding assays. Radioactive in vitro-translated MEF2C was incubated with GSTPPARa. After incubation, proteins bound to the GST fusion protein were subjected to SDS-PAGE and fluorography. As shown in Figure 5A , the MEF2C band was observed when the products of the specific in vitro translation were incubated with GST-PPARa but not with GST beads. In order to check whether this interaction was ligand dependent, we performed the same experiment with limiting amounts of the GSTPPARa protein in the presence or in the absence of a PPARa specific ligand. Figure 5B shows how this interaction is independent of the presence of the ligand.
Synergy between MEF2C and PPARa is influenced by the separation between them
To further investigate the synergy between MEF2C and PPARa, a collection of luc reporter constructs were generated in which the mutation of the MEF-2 site that abolished the binding of MEF2C was performed in the context of the human CPT1b gene promoter (pCPTmutMEF). We also made different versions in which either a sequence of 5 nt (half turn) (pCPT-M5) or 10 nt (a whole turn) (pCPT-M10) of DNA helix were introduced to separate the MEF2 site from the PPRE sequences in pCPTluc. While assaying relative basal activities for each plasmid in C2C12 cells ( Figure 6A ), we found that the mutation of the MEF2C responsive sequence produces a little decrease in basal activity and a clear reduction of the activity in the presence of PPAR.
Showing the functionality of the interaction between PPAR and MEF2C, only those constructs that maintained the natural spatial disposition of the binding sites for these proteins respect de DNA helix ( pCPT and pCPT-M10) were able to show high PPARa responsiveness, whereas those in which the spatial arrangement was disrupted ( pCPT-M5) failed ( Figure 6B ). Taken together, these results demonstrate that the interaction and synergy between MEF2C and PPARa/ RXRa show a strong dependence on a precise arrangement of activator recognition sites.
DISCUSSION
Interaction between transcription factors that bind to different sequences within a promoter can lead to synergistic effects on transcriptional activation. In this report, we show a synergistic activation of the CPT1b gene promoter by the heterodimer of nuclear receptors PPARa-RXRa and the myogenic factor MEF2C. We and others had previously demonstrated that the human CPT1b gene is a target for PPARs and had localized the PPAR responsive element (PPRE) upstream of the first exon (6) (7) (8) . It has been previously shown that the CPT1b gene promoter contains a MEF2 binding site upstream of exon 1A, flanking the PPRE (19) . The vicinity of these DNA elements It has been suggested recently that PPARd plays a pivotal role in the control of both the program for fatty acid oxidation and the CPT1b promoter in the skeletal muscle (32, 33) . Although not shown in this paper, PPARd and PPARg are also able to physically interact with MEF2C in vitro, and therefore, this interaction could be physiologically relevant in different tissues with different levels of the PPAR isotypes.
The identity of the protein that binds to the MEF2 sequence of the CPT1b gene in muscle cannot be entirely established. Till date, four different MEF2 proteins have been identified MEF2A, MEF2B, MEF2C and MEF2D. In skeletal muscle cells in culture, MEF2D has been reported to be expressed in proliferating myoblasts prior to the onset of differentiation, MEF2A protein appears as cells enter the differentiation pathway and MEF2C is expressed late in the differentiation program (34) . In agreement with the expression patterns of MEF2 proteins in myotube culture and with previously published observations that both MEF2A and MEF2C bind to the CPT1b MEF2 binding site (19) , we believe that MEF2C is responsible for the activation of the CPT1b gene.
PGC-1 is a coactivator of MEF2C and can control the level of endogenous GLUT4 gene expression in muscle (27) . It has also been shown that PGC-1 and MEF2A synergistically activate the CPT1b gene promoter (28) . Our results point to the possibility of a simultaneous interaction between PPAR, MEF2C and PGC1 forming a ternary complex and creating a unique surface that interacts with the transcription machinery more efficiently that any of the individual factors alone. The localization of the regions involved in the interaction between PPAR and MEF2C will help us to solve this issue. Alternatively, the interaction of each of these factors could modify the chromatin structure, facilitating the action of the next. In this sense, Huang et al. (35) demonstrated that promoter context affects the transcriptional activation by MyoD through E-boxes, so that neighboring proteins can recruit different associated factors to the promoter, or influence the conformation of the promoter DNA and/or of the protein-E-box complex.
A number of studies have examined the transactivating properties of the MEF2 proteins, which were originally studied in their role as transcriptional regulators of myogenic cells, including interactions with other transcription factors such as myogenin and MyoD (36, 37) . In particular, several studies have reported the physical or functional interaction between myogenic proteins and members of the nuclear receptor superfamily. Thus, it has been demonstrated that MEF-2A and the TR receptor interact synergistically to activate the a-cardiac MHC gene expression (38) . A functional cooperation between MyoD, MEF2 and TRa1 is sufficient for the induction of GLUT4 gene transcription (39) . The interaction between MyoD and RARa has also been demonstrated (40) and a functional interaction between MyoD and PPAR proposed (41) . The transcriptional coactivator PGC-1 mediates an increase in GLUT4 expression, by binding to and coactivating MEF2C (27) . Other coactivators such as CBP/p300 (25) or the Glucocorticoid Receptor Interacting Protein 1 (GRIP-1) (42), which functions as a cofactor for several nuclear receptors, has been shown to physically interact with both MyoD and MEF-2. The particular spatial arrangement of PPAR-, MEF2-and MyoD-binding sequences along the human CPT1b promoter is highly conserved in mouse, sheep and rat CPT1b genes (18) . Besides the interaction between PPARa and MEF2C shown in this paper, interactions between RXR or PPAR and MyoD are probable, but they are yet to be demonstrated.
In summary, the combination of cis elements in the promoter of the CPT1b gene maximally induces the expression of this gene in response to a combination of different signals. Thus, it seems likely that the concurrence of myogenic and metabolic signals generates a transcriptionaly permissive conformation of the CPT1b gene promoter that gives rise to a synergistic maximal transcription of the gene in those tissues containing the corresponding transcription factors (MEF2C, PPARa/RXRa) and in the presence of the metabolic substrate of the enzyme, the fatty acids that activate PPARa. for PPARa, RXRa, MEF2C and PGC-1. We are also grateful to Robin Rycroft of the Language Service for valuable assistance in the preparation of the English manuscript. This research was supported by Grants PB97-0958 and SAF2001-2923-C02-01 from Direcci o on General de Investigaci o on Científica y T e ecnica, a Grant from the FIS of the Instituto de Salud Carlos III, Red de Centros RCMN (C03/08) and the Fundaci o o la Marat o o de TV3. A.B. and J.R. were Predoctoral fellows from Generalitat de Catalunya.
